the aid library

LIST OPTIONS

Filter

1326

Sort by:

Direction:

Download (626)

View PDF (1259)

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti... more

Download (26)

View PDF (27)

Management of chronic obstructive pulmonary disease—A position statement of the South African Thoracic Society: 2019 update

Abdool-Gaffar, M. S.; Calligaro, G.; Wong, M.L. et al. Journal of Thoracic Disease (2019) CC2

The document outlines the 2019 update to the South African guideline for managing chronic obstructive pulmonary disease (COPD). It emphasizes the importance of early diagnosis, prevention through smoking cessation, use of bronchodilators as primary pharmacotherapy, and a comprehensive approach to pa... more

Download (43)

View PDF (42)

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the Eur

Marx, N.; Federici, M.; Schütt, K. et al. European Heart Journal (2023) CC

Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f... more

Download (49)

View PDF (20)

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2024

American Diabetes Association Professional Practice Committee Volume 47, Issue Supplement_1 January 2024 (2024) CC2

Ensure treatment decisions are timely, rely on evidence-based guidelines, capture key elements within the social determinants of health, and are made collaboratively with people with diabetes and care partners based on individual preferences, prognoses, comorbidities, and informed ﬁnancial conside... more

Download (130)

View PDF (178)

COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection

Anaya-Covarrubias, J.Y.; et al. (2022) C1

Curr Opin Pharmacol . 2022 Apr;63:102203.doi: 10.1016/j.coph.2022.102203. Epub 2022 Feb 11. The COVID-19 pandemic has widespread economic and social effects on Latin America (LA) and the Caribbean (CA). This region, which has a high prevalence of chronic diseases, has been one of the most affected... more

Download (108)

View PDF (563)

Self-learning course: Clinical diagnosis and management of dengue

Pan American Health Organization PAHO ; World Health Organization WHO (2021) C_WHO

This first online course is geared at helping healthcare workers in diagnosing and managing all aspects of dengue in order to avoid complications and fatalities. This course was developed with a comprehensive vision. It is divided into seven modules that include: Epidemiological informatio... more

Download (650)

View PDF (367)

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

World Health Organization WHO (2022) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (117)

View PDF (124)

Checklist and reference list for developing and reviewing a national strategic plan for HIV

UNAIDS (2020) C_WHO

The checklist and reference list has two parts: high-level cross-cutting content (Part A) and specific programme content (Part B). Part A applies to all countries and contains situation and response analysis, the NSP development process, the goal, targets and priority-setting of the NSP and the prin... more

Download (654)

View PDF (817)

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed.
recommended

The Republic of the Union of Myanmar, Ministry of Health, Department of Health, National AIDS Programme World Health Organization (WHO), Country Office for Myanmar (2017) C1

These guidelines aim to guide all health care providers in Myanmar, accommodating the situation of different settings in the context of progressive decentralization of HIV services. Notable changes from the previous edition include:
• diagnosis of HIV
• update on the initiation of ART<... more

Download (24)

View PDF (26)

Under- and over-diagnosis of COPD: a global perspective

Ho T., Cusack R.P., Chaudhary N. et al. Breathe, part of the European Respiratory Society (ERS) (2019) CC2

The article "Under- and over-diagnosis of COPD: a global perspective" reviews the worldwide variation in the prevalence of chronic obstructive pulmonary disease (COPD) and issues related to its misdiagnosis. It highlights that COPD is under-diagnosed due to factors such as limited access to spiromet... more

Download (19)

View PDF (19)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

Iheanacho, I.; Zhang, S.; King, D.; et al. International Journal of Chronic Obstructive Pulmonary Disease (2022) CC2

The article "Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review" examines the financial impact associated with moderate-to-very severe COPD. The review analyzes studies published between 2006 and 2016 that discuss healthcare resource utilization (HRU), di... more

Download (22)

View PDF (21)

Global strategy for prevention, diagnosis and management of COPD: 2023 Report

Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2023) CC2

The GOLD 2023 report provides a comprehensive update on the global strategy for diagnosing, managing, and preventing chronic obstructive pulmonary disease (COPD). It emphasizes that COPD is a leading cause of death worldwide, driven by risk factors such as tobacco smoking, air pollution, and genetic... more

Download (30)

View PDF (25)

The natural history of chronic obstructive pulmonary disease

Mannino, D.M.; Watt, G.; Hole, D.; et al. European Respiratory Journal (ERJ) (2006) CC2

The article from the European Respiratory Journal discusses the natural history of chronic obstructive pulmonary disease (COPD), emphasizing its increasing global impact on morbidity and mortality. It highlights that while cigarette smoking is a primary risk factor, other influences such as environm... more

Download (29)

View PDF (19)

The many faces of diabetes. Is there a need for re-classification? A narrative review

Sakran, N.; Graham, Yiitka.; Pintar, T.; et al. BMC Endocrine Disorders Volume 22 Article Number 9 (2022) CC

The alarming rise in the worldwide prevalence of obesity and associated type 2 diabetes mellitus (T2DM) have reached epidemic portions. Diabetes in its many forms and T2DM have different physiological backgrounds and are difficult to classify. Bariatric surgery (BS) is considered the most effective ... more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (103)

View PDF (1378)

Cancer in sub-Saharan Africa
recommended

Ngwa, W.; et al. Lancet Oncology Commission (2022) C2

Lancet Oncol 2022; 23: e251–312Published OnlineMay 9, 2022 https://doi.org/10.1016/S1470-2045(21)00720-8 In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions, data estimates show a major increase in cancer mo... more

Download (127)

View PDF (144)

Tuberculosis in the Americas. Regional Report 2020

Pan American Health Organisation PAHO (2021) C_WHO

This regional report on the situation of tuberculosis (TB) in the Americas contains information from 2019, provided by the countries of the Region through the World Health Organization TB data collection system. These data have been consolidated and analyzed at the regional level. In addition to pre... more

Download (131)

View PDF (174)

Estimating mortality from COVID-19 - Scientific brief (4 August 2020)

World Health Organization WHO (2020) C_WHO

For COVID-19, as for many infectious diseases, the true level of transmission is frequently underestimated because a substantial proportion of people with the infection are undetected either because they are asymptomatic or have only mild symptoms and thus typically fail to present at healthcare fac... more

Download (37)

View PDF (42)

South African cardiovascular risk stratification guideline for non-cardiac surgery

Alphonsus, C.; Naidoo, N.; Motshabi, P. et al. South African Medical Journal (2021) CC

The South African (SA) guidelines for cardiac patients for non-cardiac surgery were developed to address the need for cardiac risk assessment and risk stratification for elective non-cardiac surgical patients in SA, and more broadly in Africa. The guidelines were developed by updating the Canadian ...Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Non-cardiac Surgery, with a search of literature from African countries and recent publications. The updated proposed guidelines were then evaluated in a Delphi consensus process by SA anaesthesia and vascular surgical experts. The recommendations in these guidelines are: 1. We suggest that elective non-cardiac surgical patients who are 45 years and older with either a history of coronary artery disease, congestive cardiac failure, stroke or transient ischaemic attack, or vascular surgical patients 18 years or older with peripheral vascular disease require further preoperative risk stratification as their predicted 30-day major adverse cardiac event (MACE) risk exceeds 5% (conditional recommendation: moderate-quality evidence). 2. We do not recommend routine non-invasive testing for cardiovascular risk stratification prior to elective non-cardiac surgery in adults (strong recommendation: low-to-moderate-quality evidence). 3. We recommend that elective non-cardiac surgical patients who are 45 years and older with a history of coronary artery disease, or stroke or transient ischaemic attack, or congestive cardiac failure or vascular surgical patients 18 years or older with peripheral vascular disease should have preoperative natriuretic peptide (NP) screening (strong recommendation: high-quality evidence). 4. We recommend daily postoperative troponin measurements for 48 - 72 hours for non-cardiac surgical patients who are 45 years and older with a history of coronary artery disease, or stroke or transient ischaemic attack, or congestive cardiac failure or vascular surgical patients 18 years or older with peripheral vascular disease, i.e. (i) a baseline risk >5% for MACE 30 days after elective surgery (if no preoperative NP screening), or (ii) an elevated B-type natriuretic peptide (BNP)/N-terminal-prohormone B-type natriuretic peptide (NT-proBNP) measurement before elective surgery (defined as BNP >99 pg/mL or a NT-proBNP >300 pg/mL) (conditional recommendation: moderate-quality evidence). Additional recommendations are given for the management of myocardial injury after non-cardiac surgery (MINS) and medications for comorbidities. more

Download (69)

View PDF (47)

Monitoring asthma in children

Pijnenburg, M.W.; Baraldi, E.; Brand, P.L. et al. European Respiratory Journal (2015) CC

The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist i... more

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support recommended

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed. recommended

Cancer in sub-Saharan Africa recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed.
recommended

Cancer in sub-Saharan Africa
recommended